| Literature DB >> 18541202 |
Souichi Shiratori1, Atsushi Yasumoto, Junji Tanaka, Akio Shigematsu, Satoshi Yamamoto, Mitsufumi Nishio, Satoshi Hashino, Rena Morita, Mutsumi Takahata, Masahiro Onozawa, Kaoru Kahata, Takeshi Kondo, Shuichi Ota, Kentaro Wakasa, Junichi Sugita, Takao Koike, Masahiro Asaka, Masaharu Kasai, Masahiro Imamura.
Abstract
Adult T cell leukemia/lymphoma (ATL) is a highly aggressive T cell malignancy, and has a poor prognosis. Recently, allogeneic-hematopoietic stem cell transplantation (allo-HSCT) has been suggested to improve the outcome. We retrospectively analyzed 15 patients with ATL who had received allo-HSCT in 2 institutions in Hokkaido, Japan. The median age of the patients was 57 years. The estimated 3-year overall survival (OS) and progression-free survival (PFS) rates were 73.3% and 66.7%, respectively. Calcineurin inhibitor dosage was reduced and administration was discontinued abruptly in 6 of the 15 patients for disease control; as a result, 4 (66.7%) of the 6 patients achieved complete response (CR) or partial response. Therefore, a graft-versus-leukemia/lymphoma (GVL) effect might be induced by discontinuation of immunosuppression. Thirteen of the 15 patients were followed up by monitoring HTLV-1 proviral DNA levels. In 10 of the 11 patients with positive HTLV-1 proviral DNA before allo-HSCT, HTLV-1 proviral DNA became undetectable at least once after allo-HSCT, and only 1 of the 5 patients in whom HTLV-1 proviral DNA became detectable after allo-HSCT relapsed. Compared to the results of past studies, these results show that allo-HSCT greatly improved the prognosis of ATL and suggest a contribution of the induction of a GVL effect.Entities:
Mesh:
Year: 2008 PMID: 18541202 DOI: 10.1016/j.bbmt.2008.04.014
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN: 1083-8791 Impact factor: 5.742